Sequence-Specific Features of Short Double-Strand, Blunt-End RNAs Have RIG-I- and Type 1 Interferon-Dependent or -Independent Anti-Viral Effects

Viruses. 2022 Jun 28;14(7):1407. doi: 10.3390/v14071407.

Abstract

Pathogen-associated molecular patterns, including cytoplasmic DNA and double-strand (ds)RNA trigger the induction of interferon (IFN) and antiviral states protecting cells and organisms from pathogens. Here we discovered that the transfection of human airway cell lines or non-transformed fibroblasts with 24mer dsRNA mimicking the cellular micro-RNA (miR)29b-1* gives strong anti-viral effects against human adenovirus type 5 (AdV-C5), influenza A virus X31 (H3N2), and SARS-CoV-2. These anti-viral effects required blunt-end complementary RNA strands and were not elicited by corresponding single-strand RNAs. dsRNA miR-29b-1* but not randomized miR-29b-1* mimics induced IFN-stimulated gene expression, and downregulated cell adhesion and cell cycle genes, as indicated by transcriptomics and IFN-I responsive Mx1-promoter activity assays. The inhibition of AdV-C5 infection with miR-29b-1* mimic depended on the IFN-alpha receptor 2 (IFNAR2) and the RNA-helicase retinoic acid-inducible gene I (RIG-I) but not cytoplasmic RNA sensors MDA5 and ZNFX1 or MyD88/TRIF adaptors. The antiviral effects of miR29b-1* were independent of a central AUAU-motif inducing dsRNA bending, as mimics with disrupted AUAU-motif were anti-viral in normal but not RIG-I knock-out (KO) or IFNAR2-KO cells. The screening of a library of scrambled short dsRNA sequences identified also anti-viral mimics functioning independently of RIG-I and IFNAR2, thus exemplifying the diverse anti-viral mechanisms of short blunt-end dsRNAs.

Trial registration: ClinicalTrials.gov NCT02735824.

Keywords: DNA virus; RIG-I; RNA therapy; RNA virus; SARS-CoV-2; adenovirus; antiviral agents; influenza virus; interferon; short double-strand blunt-end RNA.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antiviral Agents / pharmacology
  • COVID-19*
  • DEAD Box Protein 58 / genetics
  • DEAD Box Protein 58 / metabolism
  • DEAD-box RNA Helicases / genetics
  • Humans
  • Influenza A Virus, H3N2 Subtype / genetics
  • Interferon Type I* / genetics
  • MicroRNAs*
  • RNA, Double-Stranded
  • SARS-CoV-2

Substances

  • Antiviral Agents
  • Interferon Type I
  • MicroRNAs
  • RNA, Double-Stranded
  • DEAD Box Protein 58
  • DEAD-box RNA Helicases

Associated data

  • ClinicalTrials.gov/NCT02735824